A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)

  • End date
    Aug 9, 2023
  • participants needed
  • sponsor
    Silenseed Ltd
Updated on 1 March 2022
measurable disease
endoscopic ultrasound
neutrophil count
cancer chemotherapy


In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment.

Primary Outcome:

  • ORR at 6 months.


In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable LAPC combined with chemotherapy treatment (Gemcitabine+nab-Paclitaxel or Folfirinox or modified Folfirinox). This will be a study to assess the response rate of the siG12D-LODER in patients with unresectable or borderline resectable LAPC. The study is of a single arm design with one arm receiving siG12D-LODER + chemotherapy.

The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.

siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and results showed high safety and tolerability profiles, with no single DLT.

Condition Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Treatment FOLFIRINOX, siG12D-LODER, Gemcitabine+nab-Paclitaxel
Clinical Study IdentifierNCT01676259
SponsorSilenseed Ltd
Last Modified on1 March 2022


Yes No Not Sure

Inclusion Criteria

Subject must be 18 years of age or older at the time of signing the informed consent
Type of Subject and Disease Characteristics
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Locally advanced pancreatic cancer stage III according to The American Joint Committee on Cancer (AJCC) and defined as T4, N (any) and M0, according to the three factors, T (tumor), N (node involvement), and M (metastases), of the National Comprehensive Cancer Network TNM classification
Allocated to receive one of the following chemotherapies: gemcitabine plus nab-paclitaxel, FOLFIRINOX or modified FOLFIRIONOX as first line treatment for pancreatic cancer
Have a target tumor that is accessible for intratumoral administration by EUS as determined by the radiologist/gastroenterologist performing the EUS intratumoral administration, according to The American Society for Gastrointestinal Endoscopy (ASGE) guidelines (<https://www.asge.org/home/practice-support/guidelines>)
Have measurable disease. Subject will have a histologically-confirmed disease and must have clinically and/or radiographically documented measurable primary disease according to RECIST v1.1. At least one site of disease must be unidimensionally measurable
Diagnostic Assessments
\. Eastern Cooperative Oncology Group (ECOG) Performance Scale of 1
\. Demonstrate adequate organ function as defined below
serum creatinine <1.6 mg/dL
international normalized ratio (INR) < 1.5 U
absolute neutrophil count (ANC) > 1.5 x 109/L
platelets 100 x 109/L
hemoglobin 9 mg/dL
alanine transaminase (ALT) and aspartate aminotransferase (AST) 5 times upper limit of normal (ULN)
bilirubin 1.5 x ULN Sex 8. Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 9. Women of childbearing potential (WOCBP): a negative serum or urine pregnancy test during screening. 10. Subject of childbearing potential, if sexually active (both men and women) must agree to use a barrier method of contraception, from the time of administration of the first treatment and for at least 8 weeks after EOT visit day
Informed Consent
\. Capable of giving signed informed consent which includes compliance with
the requirements and restrictions listed in the informed consent form (ICF)
and in this protocol

Exclusion Criteria

Evidence of metastatic disease
Other malignancy that would interfere with the current intervention
Any evidence of ascites (beyond trace)
Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers from which the subject has been disease-free for at least 2 years
History of clinically significant coagulopathy
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Subjects are excluded from the study if any of the following criteria apply
Medical Conditions
Females who are pregnant or breast-feeding
Subjects with resectable pancreatic cancer
Bulky celiac adenopathy (2.5 cm) or non-adenocarcinoma histology
Major surgery, other than diagnostic surgery, within 4 weeks prior to study entry without complete recovery
New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 4 months prior to the first chemotherapy cycle Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study
Prior/Concomitant Therapy
\. Any prior therapy for the treatment of pancreatic malignancy (including
chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery
or irradiation, whether conventional or investigational)
\. Prior therapy with any hypoxic cytotoxic agent (hypoxia-targeting drugs)
Prior/Concurrent Clinical Study Experience
\. Subjects who are participating or participated in an investigational drug
or device study (within 28 days prior to study entry from the last study dose
Other Exclusions
\. Unwillingness or inability to comply with the study protocol for any
\. Known allergy to sesame oil
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note